Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay K Nooka

Showing results (61-70 of 150) with videos related to

Pageof 15
Sort By:
Cancer|April 6, 2019
Daratumumab in multiple myelomaAjay K Nooka, Jonathan L Kaufman, Craig C Hofmeister, et al.
Leukemia|January 26, 2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myelomaShannon M Matulis, Vikas A Gupta, Paola Neri, et al.
Pharmacotherapy|February 5, 2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantAkhilesh Sivakumar, Evan B Bryson, Kevin H Hall, et al.
Cancer|October 18, 2018
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agentsRoberto Mina, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2025
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple MyelomaAjai Chari, Susan Bal, Sikander Ailawadhi, et al.
JCO Oncology Practice|July 7, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib InductionLaura F Sun, Kathryn T Maples, Kevin H Hall, et al.
Cancer|November 14, 2023
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 studyAjay K Nooka, Cesar Rodriguez, María Victoria Mateos, et al.
Journal of Stem Cell Research & Therapy|October 3, 2017
Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County HospitalHyun D Yun, Tehseen Dossul, Leon Bernal-Mizrachi, et al.
Blood Cancer Journal|January 6, 2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I StudyJonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 22, 2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaJonathan L Kaufman, Roberto Mina, Jatin J Shah, et al.
Pageof 15

Showing results (61-70 of 150) with videos related to

Sort By:
Pageof 15
Cancer|April 6, 2019
Daratumumab in multiple myelomaAjay K Nooka, Jonathan L Kaufman, Craig C Hofmeister, et al.
Leukemia|January 26, 2019
Functional profiling of venetoclax sensitivity can predict clinical response in multiple myelomaShannon M Matulis, Vikas A Gupta, Paola Neri, et al.
Pharmacotherapy|February 5, 2022
Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantAkhilesh Sivakumar, Evan B Bryson, Kevin H Hall, et al.
Cancer|October 18, 2018
Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agentsRoberto Mina, Nisha S Joseph, Jonathan L Kaufman, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2025
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple MyelomaAjai Chari, Susan Bal, Sikander Ailawadhi, et al.
JCO Oncology Practice|July 7, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib InductionLaura F Sun, Kathryn T Maples, Kevin H Hall, et al.
Cancer|November 14, 2023
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 studyAjay K Nooka, Cesar Rodriguez, María Victoria Mateos, et al.
Journal of Stem Cell Research & Therapy|October 3, 2017
Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County HospitalHyun D Yun, Tehseen Dossul, Leon Bernal-Mizrachi, et al.
Blood Cancer Journal|January 6, 2019
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I StudyJonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 22, 2020
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaJonathan L Kaufman, Roberto Mina, Jatin J Shah, et al.
Pageof 15